country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-P11288A

Copy Link Print Information

ANT308 TFA

Revisión del cliente

Based on 1 Customer Validation

ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM).

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.57%
Fòrmula: C₁₅₆H₂₆₁N₄₇O₄₀S·xC₂HF₃O₂
Peso molecular:3467.10 (free base)

Almacenamiento:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ANT308 TFA Chemical Structure

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- In Vitro
- In Vivo
Chemical Information
Solvente y solubilidad
- In Vitro
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas PACAP Receptor :

In Vitro

ANT308 (0.1-10 μM, 72 h) TFA reduces the viability of B16F10 and HT-144 cells dose-dependently^[2].
ANT308 (10 μM, 72 h) TFA decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells^[2].
ANT308 (10 μM, 8 h) TFA significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines^[2].
ANT308 (72 h) TFA reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

B16F10 and HT-144 cells
Concentration:

0.1, 1, 5 and 10 μM
Incubation Time:

72 h
Result:

Decreased the numbers of viable B16F10 and HT-144 cells by around 46% and 27%, respectively, compared to control cultures with 5 μM twice daily.

Cell Cycle Analysis^[2]

Cell Line:

B16LS9 and Mel 290 cells
Concentration:

10 μM
Incubation Time:

72 h
Result:

Decreased cells in the S phase.

Apoptosis Analysis^[2]

Cell Line:

B16LS9 and Mel 290 cells
Concentration:

10 μM
Incubation Time:

72 h
Result:

Increased percentages of apoptotic cells.

Cell Migration Assay ^[2]

Cell Line:

B16LS9, B16F10, Mel 290 cells, HT-144 cells
Concentration:

10 μM
Incubation Time:

8 h
Result:

Significantly inhibited cell migration in the B16LS9, Mel290, and HT-144 cell lines.

In Vivo

ANT308 (100 μg/100 μL PBS, s.c., twice a day for 10 days) TFA reduces the number and size of liver metastases of mice following intraocular or subcutaneous melanoma injection, and shows a trend toward reducing tumor volume at the primary tumor site^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

B16LS9 induced UVM model and B16LS9 or B16LS9 induced subcutaneous melanoma model established in female C57BL6/J mice (8-10 weeks) and NRG (NOD Rag gamma) mice (10-11 months old)^[2]
Dosage:

100 μg/100 μL PBS
Administration:

Subcutaneous injection (s.c.), twice a day for 10 days
Result:

Significantly reduced the number of liver metastases.
Reduced MCAM, but had no significant effect on N-cadherin expression.
had no significant effect on subcutaneous tumor volume.

Chemical Information

Appearance Solid
Peso molecular 3467.10 (free base)
Fòrmula C₁₅₆H₂₆₁N₄₇O₄₀S·xC₂HF₃O₂
Color White to off-white
Sequence

Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Ser-Asp-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Leu-Ile-Leu-Asn
Sequence Shortening

KPRRPYTSDYTRLRKQMAVKKYLNLILN
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvente y solubilidad

In Vitro:

DMSO : ≥ 100 mg/mL

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Lester C, et al. Chemical Modifications to Enhance the Drug Properties of a VIP Receptor Antagonist (ANT) Peptide. Int J Mol Sci. 2024 Apr 16;25(8):4391.

[2]. Wang W, et al. Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis. Cancer Lett. 2025 Sep 28;628:217855. [Content Brief]

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto

Amount: USD 0.00

Actividad biológica
- Descripciòn
- In Vitro
- In Vivo
Chemical Information
Solvente y solubilidad
- In Vitro
Pureza y Documentación
Referencias

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

ANT308 TFA

Peptide Library

Ver todos los productos específicos de isoformas PACAP Receptor